Adimab, Merck, Pfizer, Roche deal

Adimab announced deals with Pfizer and an undisclosed company to use its yeast-based antibody discovery technology to identify fully human antibodies. Adimab will identify mAbs against undisclosed CNS/pain targets for Pfizer, which will have rights to commercialize the resulting mAbs. Adimab will identify mAbs against an undisclosed cancer target from the undisclosed company, which will have rights to commercialize the resulting mAbs. Adimab will receive undisclosed upfront payments and licensing fees and is eligible for milestones and royalties. Further terms were not disclosed. ...